Journal
ELIFE
Volume 11, Issue -, Pages -Publisher
eLIFE SCIENCES PUBL LTD
DOI: 10.7554/eLife.77072
Keywords
prostate cancer; Capicua; ERF; ETS transcription factors; Human
Categories
Funding
- National Cancer Institute [K08CA222625, 5R37CA255453, P30CA082103]
- Benioff Initiative for Prostate Cancer Research Awards
- National Research Foundation of Korea [NRF-2020R1A6A3A03039483]
Ask authors/readers for more resources
This study reveals that the concurrent loss of CIC and ERF can drive prostate oncogenesis by mutually repressing ETS transcription factor ETV1. Targeting ETV1 can limit the growth of CIC and ERF-deficient prostate cancer.
Human prostate cancer can result from chromosomal rearrangements that lead to aberrant ETS gene expression. The mechanisms that lead to fusion-independent ETS factor upregulation and prostate oncogenesis remain relatively unknown. Here, we show that two neighboring transcription factors, Capicua (CIC) and ETS2 repressor factor (ERF), which are co-deleted in human prostate tumors can drive prostate oncogenesis. Concurrent CIC and ERF loss commonly occur through focal genomic deletions at chromosome 19q13.2. Mechanistically, CIC and ERF co-bind the proximal regulatory element and mutually repress the ETS transcription factor, ETV1. Targeting ETV1 in CIC and ERF-deficient prostate cancer limits tumor growth. Thus, we have uncovered a fusion-independent mode of ETS transcriptional activation defined by concurrent loss of CIC and ERF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available